Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The prevalence and prognostic value of KRAS co-mutation subtypes in Chinese advanced non-small cell lung cancer patients.

Cancer medicine - 1 Jan 2020

Cai Dongjing, Hu Chengping, Li Li, Deng Shichao, Yang Jing, Han-Zhang Han, Li Min

Abstract excerpt

OBJECTIVE: KRAS mutation plays a critical role in the initiation and development of non-small cell lung cancer (NSCLC). KRAS-mutant patients exhibit diverse response to chemotherapy. KRAS co-mutation subtypes and their prognosis value in advanced Chinese NSCLC patients remain largely elusive. METHODS: A total of 1126 Chinese advanced NSCLC patients from Xiangya hospital were screened by capture-based ultra-deep...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to AMP-Activated Protein Kinase Kinases
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Kaplan-Meier Estimate

Share to Neoplasm Staging

Share to Pemetrexed

Share to Progression-Free Survival

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 31709742
DOI: 10.1002/cam4.2682
PMCID: PMC6943152

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The prevalence and prognostic value of KRAS co-mutation subtypes in Chinese advanced non-small cell lung cancer patients.PMID 31709742Read ↗

Prognostic Impact of KRAS-TP53 Co-Mutations in Patients with Early-Stage Non-Small Cell Lung Cancer: A One Institution Retrospective AnalysisSemantic proximity Read ↗

Coexisting driver alterations in non-small cell lung cancer: Prevalence, clonal architecture, and impact on survival and progression.Semantic proximity Read ↗

EGFR-mutant lung adenocarcinoma harboring co-mutational tumor suppressor genes predicts poor prognosis.Semantic proximity Read ↗

The co-mutation of EGFR and tumor-related genes leads to a worse prognosis and a higher level of tumor mutational burden in Chinese non-small cell lung cancer patientsSemantic proximity Read ↗

KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing.Semantic proximity Read ↗

Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer.Semantic proximity Read ↗

K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic PathwaysSemantic proximity Read ↗

TP53 co-mutations are associated with elevated PD-L1 expression and high tumor mutational burden in non-small cell lung cancer: insights from comprehensive genomic profilingSemantic proximity Read ↗

[Gene mutation profiles and clinicopathological features of patients with non-small cell lung cancer harboring KRAS G12C mutation: a single-center retrospective study].Semantic proximity Read ↗

Impact of KRASG12D subtype and concurrent pathogenic mutations on advanced non-small cell lung cancer outcomes.Semantic proximity Read ↗

The prevalence and real-world therapeutic analysis of Chinese patients with KRAS-Mutant Non-Small Cell lung cancer.Semantic proximity Read ↗

New Horizons in KRAS-Mutant Lung Cancer: Dawn After DarknessSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.